PRAME and Miyoshi myopathy: This suggests that PRAME might be a potentially ideal indicator for the distinction between DS‐AMKL and DS‐TMD cases.38 Furthermore, it is well known that Wilms’ tumour gene 1 (WT1) gene is a tumour biomarker for a wide variety of haematological malignancies.39 Hence, the combination of these two tumour biomarkers might cover a broad range of patients with leukaemia.40 Furthermore, malignant plasma cells from the majority of MM patients express MAGE‐1, MAGE‐3 and PRAME.